0
Diffuse Lung Disease: Fellow Case Report Poster - Diffuse Lung Disease I |

Carfilzomib Pulmonary Toxicity

Anita Bhagavath, MD; Alexander Geyer, MD
Author and Funding Information

Memorial Sloan Kettering, New York, NY


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):492A. doi:10.1016/j.chest.2016.08.506
Text Size: A A A
Published online

Extract

SESSION TITLE: Fellow Case Report Poster - Diffuse Lung Disease I

SESSION TYPE: Affiliate Case Report Poster

PRESENTED ON: Tuesday, October 25, 2016 at 01:30 PM - 02:30 PM

INTRODUCTION: This is a case of a patient with multiple myeloma who developed pulmonary toxicity following administration of Carfilzomib, a proteasome inhibitor.

CASE PRESENTATION: A 72yo M with a history of Multiple Myeloma s/p two autologous stem cell transplants (5/2011, 3/2015), s/p Lenalidomide, with a relapse in 11/2015, began treatment with Carfilzomib and dexamethasone in 12/21/2015. He developed dyspnea on exertion, fatigue and a dry cough after his second dose. These symptoms worsened with each subsequent dose until the medication was discontinued on 1/26/2016. A CT chest on 2/9/2016 (Fig 1) revealed diffuse bilateral ground glass micronodular opacities and increased reticular markings. His symptoms improved slightly, but continued to persist and he was referred to pulmonary clinic. On physical exam, he had diffuse crackles on lung auscultation. PFTs revealed a severe restrictive ventilatory defect, with severely reduced diffusion capacity and desaturation to 84% on exertion. Peripheral infectious workup was negative. Repeat CT 3/1/2016 (Fig 2) revealed a slight decrease in the opacities. The etiology was uncertain, but the temporal relationship of symptom onset to Carfilzomib administration, along with symptomatic improvement since discontinuation of the drug argued for drug-induced pneumonitis. He was started empirically on prednisone 40mg daily for presumed drug-induced pneumonitis, with Bactrim prophylaxis, with further clinical improvement.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Fatal pulmonary toxicity due to carfilzomib (Kyprolis™). J Oncol Pharm Pract 2016;22(5):720-4.
Carfilzomib reverses pulmonary arterial hypertension. Cardiovasc Res 2016;110(2):188-99.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543